MeiraGTx
Develops locally delivered AAV gene therapies and manufactures its own viral vectors.
$13.82
After-hours close0.00 (0.00%)
At close$13.82(−2.26%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions 86.48%Insiders 15.19%
Institutions and insiders are filed separately and overlap, so together they can pass the whole company. No split is drawn from them.
Shares outstanding 92.61M · Float 70.14M · 75.7% free float
Institutions13F, as of Jun 30, 2026
160 holders · 80.09M shares · 39 new positions · 119 increased · 23 reduced · 15 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Sanofi | 12.20M | 13.17% | 0 | Jul 28, 2026 |
| Perceptive Advisors LLC | 10.79M | 11.65% | +460.6K | Aug 14, 2026 |
| Rubric Capital Management LP | 9.10M | 9.83% | +2.10M | Aug 14, 2026 |
| Johnson & Johnson | 6.64M | 7.17% | 0 | Aug 6, 2026 |
| BlackRock, Inc. | 4.76M | 5.14% | +1.59M | Aug 7, 2026 |
| Adage Capital Partners GP, L.L.C. | 4.40M | 4.75% | +400.0K | Aug 14, 2026 |
| Opaleye Management Inc. | 3.55M | 3.83% | +1.43M | Aug 14, 2026 |
| Millennium Management LLC | 2.97M | 3.21% | −493.9K | Aug 14, 2026 |
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Perceptive Advisors LLCincl. Joseph Edelman, Perceptive Life Sciences Master Fund, Ltd. | 12.60% | 11.74M | 13D | Apr 24, 2026 ↗ |
| Rubric Capital Management LP | 7.90% | 6.18M | 13G | Feb 13, 2026 ↗ |
InsidersForm 4
| Insider | Role | Shares | % outstanding | Filed |
|---|---|---|---|---|
| Perceptive Advisors LLC | director, 10 percent owner: | 10.79M | 11.65% | Apr 23, 2026 |
| Alexandria Forbes | director, officer: PRESIDENT & CEO | 1.33M | 1.43% | Aug 18, 2026 |
| Richard Giroux | officer: CFO & COO | 908.5K | 0.98% | Jul 21, 2026 |
| Stuart Naylor | officer: CHIEF SCI OFCR, OPHTHALMOLOGY | 640.8K | 0.69% | Jul 7, 2026 |
| Keith R. Harris | director | 200.0K | 0.22% | Jun 10, 2026 |
| Robert K. Zeldin | officer: CHIEF MEDICAL OFFICER | 146.2K | 0.16% | Apr 28, 2026 |
| Robert J. Wollin | officer: GENERAL COUNSEL AND SECRETARY | 57.4K | 0.06% | Feb 23, 2026 |
2 ten-percent owners hold 17.51M shares by Form 4 — the 13D/G table above shows those stakes, the figure above counts officers and directors only · 7 people have not refiled in the last 18 months (6.91M shares), so they are not in the figure above
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Aug 18, 2026 | Alexandria Forbesdirector, officer: PRESIDENT & CEO | Sale | 62,000 | $13.86 | 1,325,695 |
| Jul 21, 2026 | Richard Girouxofficer: CFO & COO | Sale | 56,000 | $12.51 | 908,530 |
| Jul 7, 2026 | Stuart Naylorofficer: CHIEF SCI OFCR, OPHTHALMOLOGY | Sale · 2 lots | 27,659 | $14.80 | 640,846 |
| May 19, 2026 | Alexandria Forbesdirector, officer: PRESIDENT & CEO | Sale | 62,000 | $9.17 | 1,387,695 |
| Apr 21, 2026 | Richard Girouxofficer: CFO & COO | Sale | 56,000 | $10.22 | 971,530 |
| Apr 7, 2026 | Stuart Naylorofficer: CHIEF DEV. OFFICER | Sale | 27,661 | $9.36 | 668,505 |
| Mar 24, 2026 | Alexandria Forbesdirector, officer: PRESIDENT & CEO | Sale | 62,000 | $7.41 | 1,449,695 |
| Oct 21, 2025 | Richard Girouxofficer: CFO & COO | Sale | 24,000 | $8.87 | 829,494 |
| Oct 7, 2025 | Alexandria Forbesdirector, officer: PRESIDENT & CEO | Sale | 47,500 | $8.39 | 1,313,983 |
CongressHouse and Senate disclosures
Not reported.